kringle-pharmaCo., Ltd.

COMPANY

Corporate information

Human body has a natural ability to repair and regenerate injured parts. Endogenous proteins called growth factors and stem cells with differentiation potency, both work together for a self-repair mechanism. Regenerative medicine, getting a lot more attention recently, deals with therapeutic approaches to regenerate damaged tissues and organs by utilizing our own repair mechanisms.

The liver is the only visceral organ that possesses remarkable capacity to regenerate. Hepatocyte growth factor, HGF, was originally identified by the Japanese scientists as a mitogenic protein stimulating liver regeneration. Through a series of studies, it was discovered that HGF plays a role as an intrinsic factor with an organotrophic role in the regeneration of various tissues and organs including the liver, the kidneys, skin, blood vessels and the nervous system. Based on the preclinical data demonstrating dramatic therapeutic efficacy of HGF in animal disease models, it becomes obvious that expectations of HGF is growing as a novel regenerative medicine for incurable diseases.

Kringle Pharma is a clinical-stage biopharmaceutical company focusing on the commercialization of HGF medicine. We contribute to the well-being of people around the world by creating new values. We have succeeded in producing the GMP-compliant recombinant human HGF for clinical development. Currently, a confirmatory Phase III study in acute spinal cord injury and a proof-of-concept Phase II study in ALS are underway in Japan. Once we confirm clinical proof-of-concept for these neuronal diseases, target indications of HGF are surely expanded to other organ diseases. Our hope is to bring happiness to patients and their family by provide innovative HGF medicine in the near future.

Kiichi Adachi
President and CEO

CORPORATE PHILOSOPHY

Corporate philosophy

We will contribute to our society and global health by research,
development and commercialization of innovative medicines for patients suffering from incurable diseases.

VALUE

Behavioral guidelines

Kringle Pharma's code of conduct:

01
We are always aware that we are performing important work that supports people’s health, and we take pride and responsibility for our actions.
02
We constantly think of new strategies to help patients suffering from diseases globally.
03
We must not forget the fact that companies are part of society, and we are being supported by many stakeholders. We discipline ourselves to avoid being criticized or misunderstood by the society.

The strengths of HGF

Regeneration of tissues and organs Treatment of incurable diseases

COMPANY NAME

Derived from the company name

Kringle Pharma , Inc.

"Kringle domain" is the name of the characteristic protein structure found in HGF, which is believed to play a role in binding mediators (e.g., membranes, other proteins or phospholipids), and in the regulation of proteolytic activity. Our company name, Kringle Pharma, is derived from this "Kringle domain" and "Pharmaceutical company".